Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis

Ebina, Kosuke; Etani, Yuki; Noguchi, Takaaki; Nakata, Ken; Okada, Seiji

doi:https://doi.org/10.1007/s00774-024-01536-0

Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis

Ebina, Kosuke; Etani, Yuki; Noguchi, Takaaki et al.

Journal of Bone and Mineral Metabolism, 2024, 43(1), 3-9

アクセス数:930件（2025-07-06 16:44 集計）

固定URL: https://hdl.handle.net/11094/98098

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
JBoneMinerMetab_s00774-024-01536-0	pdf	なし	624 KB	386	2024.09.19

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis
著者	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 著者名 Ebina, Kosuke
	NRID 1000060898930 1000060898930 ORCID 0000-0001-5741-5969 0000-0001-5741-5969 researchmap permalink Yetani0302 Yetani0302 著者名 Etani, Yuki
	NRID 1000050812294 1000050812294 researchmap permalink takaakinoguchi takaakinoguchi ORCID 0000-0001-9938-6780 0000-0001-9938-6780 著者名 Noguchi, Takaaki
	NRID 1000000283747 1000000283747 researchmap permalink ken-nakata ken-nakata Scopus Author ID 7402151308 7402151308 著者名 Nakata, Ken
	NRID 1000030448435 1000030448435 ORCID 0000-0002-5107-8209 0000-0002-5107-8209 researchmap permalink okadaseiji okadaseiji Scopus Author ID 35079139100 35079139100 著者名 Okada, Seiji
キーワード等	Abaloparatide
	Osteoanabolic agent
	Postmenopausal osteoporosis
	Romosozumab
	Teriparatide
内容	The version of record of this article, first published in Journal of Bone and Mineral Metabolism, is available online at Publisher’s website: https://doi.org/10.1007/s00774-024-01536-0.
抄録	In the management of osteoporosis, anti-resorptive agents serve as a primary therapeutic approach. However, in cases where individuals exhibit an increased susceptibility to fractures, such as those characterized by severe low bone mass or a history of vertebral or hip fractures that markedly diminish life expectancy, the immediate reduction of fracture risk through the administration of osteoanabolic agents could be beneficial. Teriparatide, available in daily, once-weekly, or twice-weekly dosages, along with abaloparatide and romosozumab, constitutes a trio of such agents. Each of these medications is defined by unique characteristics, distinct efficacy profiles, and specific adverse effects. There is growing evidence to suggest that these agents have a superior effect on enhancing bone mineral density and reducing fracture incidence when compared to traditional bisphosphonate therapies. Nonetheless, their employment demands thorough consideration of clinical indications, which includes evaluating economic factors, the frequency of injections required, and the potential for adverse effects. The objective of this review is to consolidate the current evidence focusing primarily on the efficacy of these agents, with the goal of enhancing understanding and aiding in making more informed treatment decisions, particularly for those individuals who are at an elevated risk of fractures.
出版者	Springer
収録物名	Journal of Bone and Mineral Metabolism
巻(号)	43(1)
ページ	3-9
刊行年月	2024-07-10
言語	英語
ハンドルURL	https://hdl.handle.net/11094/98098
PISSN	09148779
eISSN	14355604
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1007/s00774-024-01536-0
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCTERMS.bibliographicCitation	Journal of Bone and Mineral Metabolism. 2024, 43(1), p. 3-9
DC.title	Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis
DC.creator	Ebina, Kosuke
	Etani, Yuki
	Noguchi, Takaaki
	Nakata, Ken
	Okada, Seiji
DC.publisher	Springer
DC.language' scheme='DCTERMS.RFC1766	英語
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-07-10
DC.identifier	https://doi.org/10.1007/s00774-024-01536-0
DC.subject	Abaloparatide
	Osteoanabolic agent
	Postmenopausal osteoporosis
	Romosozumab
	Teriparatide
DC.description	The version of record of this article, first published in Journal of Bone and Mineral Metabolism, is available online at Publisher’s website: https://doi.org/10.1007/s00774-024-01536-0.
DCTERMS.abstract	In the management of osteoporosis, anti-resorptive agents serve as a primary therapeutic approach. However, in cases where individuals exhibit an increased susceptibility to fractures, such as those characterized by severe low bone mass or a history of vertebral or hip fractures that markedly diminish life expectancy, the immediate reduction of fracture risk through the administration of osteoanabolic agents could be beneficial. Teriparatide, available in daily, once-weekly, or twice-weekly dosages, along with abaloparatide and romosozumab, constitutes a trio of such agents. Each of these medications is defined by unique characteristics, distinct efficacy profiles, and specific adverse effects. There is growing evidence to suggest that these agents have a superior effect on enhancing bone mineral density and reducing fracture incidence when compared to traditional bisphosphonate therapies. Nonetheless, their employment demands thorough consideration of clinical indications, which includes evaluating economic factors, the frequency of injections required, and the potential for adverse effects. The objective of this review is to consolidate the current evidence focusing primarily on the efficacy of these agents, with the goal of enhancing understanding and aiding in making more informed treatment decisions, particularly for those individuals who are at an elevated risk of fractures.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	98098
citation_title	Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis
citation_author	Ebina, Kosuke
	Etani, Yuki
	Noguchi, Takaaki
	Nakata, Ken
	Okada, Seiji
citation_publisher	Springer
citation_language	英語
citation_date	2024-07-10
citation_journal_title	Journal of Bone and Mineral Metabolism
citation_volume	43
citation_issue	1
citation_firstpage	3
citation_lastpage	9
citation_doi	https://doi.org/10.1007/s00774-024-01536-0
citation_public_url	https://hdl.handle.net/11094/98098

Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis

閲覧可能ファイル

論文情報

論文詳細を表示